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sildenaﬁl. CONCLUSIONS: Patients with ED without other rel-
evant concomitant diseases showed better clinical response to
treatment than those suffering from associated conditions.
PIH22
LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS
QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR
A NEW COMBINED ORAL CONTRACEPTIVE PILL
Fernandez N1, Mear I2, Moos R3, Johannes EJ4
1Mapi Reserach Institute, Lyon, France, 2Mapi Research Institute, Lyon,
France, 3Standford School of Medicine, Stanford, CA, USA,
4ORGANON, BH Oss,The Netherlands
OBJECTIVES: Prior to use in an international study by NV
Organon, the original 48-item menstrual Distress Questionnaire
(MDQ), underwent linguistic validation in 26 languages. The
original scale was developed in US English to assess the impact
of common symptoms and feelings associated with the menstrual
cycle. A rigorous methodology was required to ensure concep-
tual equivalence and cultural relevance across different lan-
guages. METHODS: The translation process was conducted by
a specialist in each target country using the following standard-
ized methodology: 1) two forward translations by professional
translators who were native speakers of the target language and
ﬂuent in English; 2) comparison and reconciliation of the trans-
lations by the specialist in the target country and the translators;
3) back-translation by a native English speaker; 4) comparison
of the original and back-translated versions; 5) review by a clin-
ician; 6) comprehension test on 5 women; and 7) review for
international comparability. RESULTS: The translation process
revealed two major challenges. First, the formulation of some
original items required the addition of a paraphrase or explana-
tion in some languages. Second, the comprehension tests revealed
that in countries where women are less used to completing ques-
tionnaires, the instructions asking the respondent to rate the
same symptom/feeling for different times during a menstrual
cycle were not always understood immediately. This required
alternative wording in some translations. CONCLUSION: The
26 language versions of the MDQ were established according to
a rigorous standardized translation methodology. The process
aims to ensure conceptual equivalence across language versions
to facilitate international comparison and pooling of data. The
linguistic validation process illustrates the value of the integra-
tion of international feedback on concepts and wording during
the translation of questionnaires.
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Erectile dysfunction (ED) is deﬁned as the persistent or recurring
incapacity to achieve or maintain sufﬁcient rigidity of the penis
to be able to have satisfactory sexual intercourse. OBJECTIVES:
To determine the clinical evaluation of the treatments prescribed
in Spain for ED in terms of efﬁcacy, patient satisfaction, onset
of action, tolerability and reproducibility of the effect.
METHODS: A retrospective epidemiological study was con-
ducted in which we collected demographic data, medical and
sexual history, concomitant medication, diagnostic and thera-
peutic procedures applied to ED and clinical response to the pre-
scribed treatment, in male patients over 18 years of age who had
visited a doctor in the 3 months prior to the start of the study.
RESULTS: Data was collected from 5281 patients. 86.8% of
those taking vardenaﬁl obtained an erection that was sufﬁcient
for satisfactory intercourse vs. 59.1% with tadalaﬁl and 45.2%
with sildenaﬁl (p < 0.0001). The time required to obtain the erec-
tion was considered satisfactory in 89.7% of the patients taking
vardenaﬁl vs. 65.2% with tadalaﬁl and 44.8% with sildenaﬁl (p
< 0.0001). The tolerability of the prescribed treatment was sat-
isfactory in 94.3% of the patients who took vardenaﬁl vs. 77.8%
with tadalaﬁl and 74.0% with sildenaﬁl (p < 0.0001). A total of
85.7% of the patients with ED who took vardenaﬁl referred they
were conﬁdent that they could obtain and maintain a sufﬁcient
erection in each new attempt vs. 57.1% with tadalaﬁl and 44.6%
with sildenaﬁl (p < 0.0001). The mean prescribed dose of var-
denaﬁl was 15.9 mg (SD 5.2), 18.6 mg (SD 6.9) for tadalaﬁl and
60.6 mg (SD 23.7) for sildenaﬁl.CONCLUSIONS: Oral treat-
ments for erectile dysfunction provide a good clinical response,
observing a statistically higher response with vardenaﬁl at a
lower dose.
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OBJECTIVE: To explore the feasibility of producing preferences
in the Italian context. METHODS: We carried out a pilot expe-
rience to assess the preferences of Italian patients (pts) suffering
from benign prostatic hyperplasia, using different techniques. Pts
expressed their opinions on different scenarios (with/without
drugs, TURP). Outcomes to be evaluated were: symptoms relief,
risk of urinary retention, adverse events (AEs) etc. Pts were asked
to: 1) rank the scenarios according to their preferences; 2) rate
(0 to 100) any scenario: and 3) express their Willingness to Pay
for each scenario. RESULTS: On a sample of 51 pts, the differ-
ent methods showed similar results except for WTP, whose ratio-
nale was difﬁcult to understand by pts. Among preference
factors, pts ranked reducing the prostate volume and the risk of
surgery at the top of the list; while reducing the risk of urinary
retention and avoiding AEs were at the end. Data processing
showed an inverse relation between preferences of minimizing
AEs and efﬁcacy. CONCLUSIONS: We found a lot of difﬁcul-
ties in measuring health preferences. The acceptance to take part
into the study was poor. It is likely that the poor acceptance
reﬂects the lack of interest by urologists and pts. Furthermore,
the number of published papers on preferences by Italian authors
is very scarce. In our opinion, likely explanations of this is that
a) in Italy the National Health Service is free/almost free for
everybody, and this leads to a difﬁcult evaluation (in economic
terms) of a health care intervention; b) scenarios to be evaluated
are theoretical, not experienced by pts; c) in a solidarity health
service (as the Italian one) the health decision-making is based
on political and social basis, and not only on economic analysis;
and d) usually the health decisions are based on a quantitative,
and not qualitative, approach.
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OBJECTIVES: To assess the inﬂuence of vardenaﬁl on treatment
satisfaction in men with erectile dysfunction (ED) and their
female partners. METHODS: This was a retrospective pooled
analysis of three multicentre, double-blind, ﬂexible-dose,
placebo-controlled clinical studies of vardenaﬁl vs. placebo for
12 weeks, in men with ED for at least 6 months duration, and
